

ChemoCentryx, Inc.  
Form 4  
December 14, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Parker Geoffrey M.

(Last) (First) (Middle)

C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE

(Street)

MOUNTAIN VIEW, CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
ChemoCentryx, Inc. [CCXI]

3. Date of Earliest Transaction (Month/Day/Year)  
12/10/2015

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |   |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|
|                                 |                                      |  |                                | (A) or (D)  | Price   |  |   |   |
| Common Stock                    | 12/10/2015                           |  | P                              | 15,379  | A \$ 7.2308<br>(1)  | 34,979   | I   | Geoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust |
|                                 | 12/11/2015                           |  | P                              | 4,621   | A   | 39,600   | I   |   |

Edgar Filing: ChemoCentryx, Inc. - Form 4

|              |  |  |                        |        |   |  |   |
|--------------|--|--|------------------------|--------|---|--|---|
| Common Stock |  |  | \$ 7,298<br><u>(2)</u> |        |   |  | Geoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust |
| Common Stock |  |  |                        | 39,600 | I |  | Geoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust |
| Common Stock |  |  |                        | 5,000  | I |  | By Delaware Charter Guarantee & Trust Company, Trustee FBO Mr. Geoffrey Monroe Parker IRA           |
| Common Stock |  |  |                        | 13,514 | D |  |   |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned |
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|---|
|--|------------------------------------|--------------------------------------|--|--------------------------------|-------------------------|--|--|--|---|

Edgar Filing: ChemoCentryx, Inc. - Form 4

|                        |   |                  |   |
|------------------------|---|------------------|---|
| Derivative<br>Security | Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | (Instr. 3 and 4) | Own<br>Follo<br>Repo<br>Trans<br>(Instr |
|------------------------|---|------------------|---|

  

|        |     |     |      |                    |       |  |
|--------|-----|-----|------|--------------------|-------|--|
| Code V | (A) | (D) | Date | Expiration<br>Date | Title | Amount<br>or<br>Number<br>of<br>Shares |
|--------|-----|-----|------|--------------------|-------|--|

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| Parker Geoffrey M.<br>C/O CHEMOCENTRYX, INC.<br>850 MAUDE AVENUE<br>MOUNTAIN VIEW, CA 94043 | X             |           |         |       |

## Signatures

/s/ Susan M. Kanaya, as Attorney-in-Fact 12/14/2015

Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
  - (1) Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from \$7.01 to \$7.53 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
  - (2) Reflects the weighted average sale price of the shares purchased. The shares were purchased in multiple trades at prices ranging from \$7.16 to \$7.43 per share, inclusive. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.